Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
As a result of the amendment to the act on promotion of employment of persons with disabilities the statutory employment rate for handicapped people was raised from 2.0% to 2.2% in April 2018. By 2021, it will be raised again by 0.1% to 2.3%. The number of jobs for handicapped people has also been increasing recently, and it is predicted that the number of jobs for people with developmental disorders will also increase. From this perspective, it is predicted that occupational safety and health engineers, such as health officers, will have more opportunities to give safety and health education to workers with developmental disorders. People with developmental disorders have various characteristics that are different from those with an ordinary type of development, and occupational health and safety engineers need to understand their characteristics when providing education for them. This report summarizes the characteristics of people with developmental disorders that occupational safety and health engineers should know when educating them.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7888/juoeh.42.89 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Same-day multiplex detection of foodborne bacterial pathogens for clinical diagnostics and food safety.
J Appl Microbiol
September 2025
Graduate Institute of Medical Sciences, National Defense Medical University, Taipei City 114201, Taiwan (R.O.C.).
Aims: This study aims to develop and evaluate a rapid and high-multiplex pathogen detection method for clinical and food specimens to address the ongoing public health threat of foodborne infections and the limitations of conventional culture-based diagnostics.
Methods And Results: The foodborne bacteria (FBB) assay integrates multiplex PCR, T7 exonuclease hydrolysis, and a suspension bead array to simultaneously detect 16 genes from 13 major foodborne bacteria. Analytical performance was evaluated using reference strains, while diagnostic performance was assessed using clinical and food samples.
Exploring Antiviral Strategies to Combat African Swine Fever.
FEMS Microbiol Rev
September 2025
CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal.
African Swine Fever (ASF), caused by the highly contagious African swine fever virus (ASFV), poses a significant threat to domestic and wild pigs worldwide. Despite its limited host range and lack of zoonotic potential, ASF has severe socio-economic and environmental consequences. Current control strategies primarily rely on early detection and culling of infected animals, but these measures are insufficient given the rapid spread of the disease.
View Article and Find Full Text PDFMisinformation in spinal cord rehabilitation on YouTube: Enhancing standards for patient safety.
J Back Musculoskelet Rehabil
September 2025
Neurology, Akdeniz University, Antalya, Turkey.
BackgroundSpinal cord injury is a complex condition affecting millions globally, often requiring extensive rehabilitation. YouTube is increasingly utilized by spinal cord injury-patients and caregivers for rehabilitation information, despite potential misinformation risks. However, few studies have assessed the quality of spinal cord injury -related content on this platform.
View Article and Find Full Text PDFElinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
Revisiting the FDA's Accelerated Approval Pathway.
JAMA
September 2025
Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.